Antitumor activity of Type i and Type III interferons in BNL hepatoma model

Cancer Immunology, Immunotherapy

Volumn 59, Issue 7, 2010, Pages 1059-1071

  Abushahba, Walid ^a   Balan, Murugabaskar ^a   Castaneda, Ismael ^b   Yuan, Yao ^b   Reuhl, Kenneth ^c   Raveche, Elizabeth ^b   De La Torre, Andrew ^b   Lasfar, Ahmed ^a   Kotenko, Sergei V ^a  

^a University of Medicine and Dentistry of New Jersey   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Dendritic cells; Hepatitis C and B virus; Hepatocellular carcinoma; Interferons; Interleukin 12; Natural killer cells

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; GLYCOPROTEIN P 15095; ANTINEOPLASTIC AGENT; INTERFERON; INTERLEUKIN 12; STAT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CANCER GENE THERAPY; CELL ISOLATION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; GROWTH INHIBITION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATOMA CELL; IMMUNE RESPONSE; IMMUNOCYTOTOXICITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYMPHOCYTE DEPLETION; LYMPHOCYTIC INFILTRATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL PROLIFERATION; CLASSIFICATION; CYTOLOGY; CYTOTOXICITY; DRUG EFFECT; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LIVER TUMOR; METABOLISM; PATHOLOGY; SPLEEN; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE I; INTERFERONS; INTERLEUKIN-12; KILLER CELLS, NATURAL; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; SPLEEN; STAT1 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 77953044883     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0831-3     Document Type: Article

References (63)

1. M Sherman 2005 Hepatocellular carcinoma: epidemiology, risk factors, and screening Semin Liver Dis 25 143 154 10.1055/s-2005-871194 15918143 (Pubitemid 40781067)
2. PA Farazi RA DePinho 2006 Hepatocellular carcinoma pathogenesis: from genes to environment Nat Rev Cancer 6 674 687 10.1038/nrc1934 1:CAS:528:DC%2BD28XosVOmsLs%3D 16929323 (Pubitemid 44286000)
3. WY Lau EC Lai 2008 Hepatocellular carcinoma: current management and recent advances Hepatobiliary Pancreat Dis Int 7 237 257 18522878
4. A Taketomi Y Soejima T Yoshizumi H Uchiyama Y Yamashita Y Maehara 2008 Liver transplantation for hepatocellular carcinoma J Hepatobiliary Pancreat Surg 15 124 130 10.1007/s00534-007-1296-4 18392704 (Pubitemid 351516969)
5. V Mazzaferro YS Chun RT Poon ME Schwartz FY Yao JW Marsh S Bhoori SG Lee 2008 Liver transplantation for hepatocellular carcinoma Ann Surg Oncol 15 1001 1007 10.1245/s10434-007-9559-5 18236119
6. V Mazzaferro JM Llovet R Miceli S Bhoori M Schiavo L Mariani T Camerini S Roayaie ME Schwartz GL Grazi R Adam P Neuhaus, et al. 2009 Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis Lancet Oncol 10 35 43 10.1016/S1470-2045(08)70284-5 19058754
7. M Sherman 2008 Recurrence of hepatocellular carcinoma N Engl J Med 359 2045 2047 10.1056/NEJMe0807581 1:CAS:528:DC%2BD1cXhtleis77E 18923166
8. CS Georgiades K Hong JF Geschwind 2008 Radiofrequency ablation and chemoembolization for hepatocellular carcinoma Cancer J 14 117 122 10.1097/PPO.0b013e31816a0fac 18391617
9. AM Di Bisceglie RL Carithers Jr GJ Gores 1998 Hepatocellular carcinoma Hepatology 28 1161 1165 10.1002/hep.510280436 1:STN:280:DyaK1cvivFGrsw%3D%3D 9755258 (Pubitemid 28450282)
10. H Nagai Y Sumino 2008 Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy Recent Pat Anticancer Drug Discov 3 220 226 10.2174/157489208786242296 1:CAS:528:DC%2BD1MXhtlCgsrs%3D 18991790
11. HB El-Serag 2002 Hepatocellular carcinoma: an epidemiologic view J Clin Gastroenterol 35 S72 S78 10.1097/00004836-200211002-00002 12394209 (Pubitemid 35278644)
12. G Fattovich G Giustina J Sanchez-Tapias C Quero A Mas PG Olivotto A Solinas P Almasio S Hadziyannis F Degos MC de Moura K Krogsgaard, et al. 1998 Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol 93 896 900 10.1111/j.1572-0241. 1998.00272.x 1:STN:280:DyaK1czgvFahuw%3D%3D 9647014 (Pubitemid 29076972)
13. M Omata H Yoshida Y Shiratori 2005 Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy Clin Gastroenterol Hepatol 3 S141 S143 10.1016/S1542-3565(05)00713-5 1:CAS:528:DC%2BD2MXhtF2ms73J 16234063 (Pubitemid 41427747)
14. SM Lin ML Yu CM Lee RN Chien IS Sheen CM Chu YF Liaw 2007 Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma J Hepatol 46 45 52 10.1016/j.jhep.2006.08.021 1:CAS:528:DC%2BD28Xht1Krs7vK 17107734 (Pubitemid 44827423)
15. ML Yu SM Lin WL Chuang CY Dai JH Wang SN Lu IS Sheen WY Chang CM Lee YF Liaw 2006 A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan Antivir Ther 11 985 994 1:CAS:528:DC%2BD2sXhtF2qt74%3D 17302368
16. JM Llovet M Sala L Castells Y Suarez R Vilana L Bianchi C Ayuso V Vargas J Rodes J Bruix 2000 Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma Hepatology 31 54 58 10.1002/hep.510310111 1:CAS:528:DC%2BD3cXks1Kquw%3D%3D 10613728
17. CM Lo CL Liu SC Chan CM Lam RT Poon IO Ng ST Fan J Wong 2007 A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma Ann Surg 245 831 842 10.1097/01.sla. 0000245829.00977.45 17522506 (Pubitemid 46809282)
18. S Pestka CD Krause MR Walter 2004 Interferons, interferon-like cytokines, and their receptors Immunol Rev 202 8 32 10.1111/j.0105-2896.2004.00204.x 1:CAS:528:DC%2BD2MXhs1OisQ%3D%3D 15546383 (Pubitemid 39576902)
19. SV Kotenko G Gallagher VV Baurin A Lewis-Antes M Shen NK Shah JA Langer F Sheikh H Dickensheets RP Donnelly 2003 IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex Nat Immunol 4 69 77 10.1038/ni875 1:CAS:528:DC%2BD38Xps1eltL8%3D 12483210 (Pubitemid 36109115)
20. P Sheppard W Kindsvogel W Xu K Henderson S Schlutsmeyer TE Whitmore R Kuestner U Garrigues C Birks J Roraback C Ostrander D Dong, et al. 2003 IL-28, IL-29 and their class II cytokine receptor IL-28R Nat Immunol 4 63 68 10.1038/ni873 1:CAS:528:DC%2BD38Xps1elt7c%3D 12469119 (Pubitemid 36104710)
21. A Lasfar A Lewis-Antes SV Smirnov S Anantha W Abushahba B Tian K Reuhl H Dickensheets F Sheikh RP Donnelly E Raveche SV Kotenko 2006 Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma Cancer Res 66 4468 4477 10.1158/0008-5472.CAN-05- 3653 1:CAS:528:DC%2BD28XjsFSlu74%3D 16618774
22. A Sato M Ohtsuki M Hata E Kobayashi T Murakami 2006 Antitumor activity of IFN-lambda in murine tumor models J Immunol 176 7686 7694 1:CAS:528: DC%2BD28Xlt1CksLg%3D 16751416
23. M Numasaki M Tagawa F Iwata T Suzuki A Nakamura M Okada Y Iwakura S Aiba M Yamaya 2007 IL-28 elicits antitumor responses against murine fibrosarcoma J Immunol 178 5086 5098 1:CAS:528:DC%2BD2sXjslWjtro%3D 17404291
24. SE Doyle H Schreckhise K Khuu-Duong K Henderson R Rosler H Storey L Yao H Liu F Barahmand-pour P Sivakumar C Chan C Birks, et al. 2006 Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes Hepatology 44 896 906 10.1002/hep.21312 1:CAS:528:DC%2BD28XhtFyqsrzI 17006906 (Pubitemid 46489554)
25. C Sommereyns S Paul P Staeheli T Michiels 2008 IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo PLoS Pathog 4 e1000017 10.1371/journal.ppat.1000017 18369468 (Pubitemid 351631092)
26. Kotenko SV, Donnelly RP (2006) Type III IFNs: the Interferon-λ family. In: Meager A (ed) The interferons: characterization and application. Wiley-VCH, Weinheim, pp 141-163
27. J Huang SV Smirnov A Lewis-Antes M Balan W Li S Tang GV Silke MM Putz GL Smith SV Kotenko 2007 Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus Proc Natl Acad Sci USA 104 9822 9827 10.1073/pnas.0610352104 1:CAS:528:DC%2BD2sXmsFSmsbo%3D 17517620 (Pubitemid 47175350)
28. Kotenko SV (2007) IFN-λs. In: Zdanov A (ed) Class II cytokines, Transworld Research Network
29. XY Fu DS Kessler SA Veals DE Levy JEJ Darnell 1990 ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains Proc Natl Acad Sci USA 87 8555 8559 10.1073/pnas.87.21.8555 1:CAS:528:DyaK3MXks1Ck 2236065
30. K Shuai C Schindler VR Prezioso JEJ Darnell 1992 Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein Science 258 1808 1812 10.1126/science.1281555 1:CAS:528: DyaK3sXlslyktw%3D%3D 1281555
31. M Mordstein G Kochs L Dumoutier JC Renauld SR Paludan K Klucher P Staeheli 2008 Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses PLoS Pathog 4 e1000151 10.1371/journal.ppat.1000151 18787692
32. D Kugel G Kochs K Obojes J Roth GP Kobinger D Kobasa O Haller P Staeheli MV von 2009 Intranasal administration of interferon-alpha reduces seasonal influenza A virus morbidity in ferrets J Virol 83 3843 3851 10.1128/JVI.02453-08 1:CAS:528:DC%2BD1MXktlSis74%3D 19193792
33. N Ank MB Iversen C Bartholdy P Staeheli R Hartmann UB Jensen F gnaes-Hansen AR Thomsen Z Chen H Haugen K Klucher SR Paludan 2008 An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity J Immunol 180 2474 2485 1:CAS:528:DC%2BD1cXhsVSgsrw%3D 18250457
34. N Ank H West C Bartholdy K Eriksson AR Thomsen SR Paludan 2006 Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo J Virol 80 4501 4509 10.1128/JVI.80.9.4501-4509.2006 1:CAS:528: DC%2BD28Xkt1Ors7g%3D 16611910
35. CA Lazaro M Chang W Tang J Campbell DG Sullivan DR Gretch L Corey RW Coombs N Fausto 2007 Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes Am J Pathol 170 478 849 10.2353/ajpath.2007.060789 1:CAS:528:DC%2BD2sXitlOlsL8%3D 17255316 (Pubitemid 47339385)
36. T Marcello A Grakoui G Barba-Spaeth ES Machlin SV Kotenko MR MacDonald CM Rice 2006 Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics Gastroenterology 131 1887 1898 10.1053/j.gastro.2006.09.052 17087946 (Pubitemid 44958521)
37. SH Hong K Kim HJ Shin SV Kotenko S Park 2007 The different effect of Interferon-lambda on Hepatitis B Virus replication in two human hepatoma cell lines Virus Res 162 245 249 10.1016/j.virusres.2007.03.006 (Pubitemid 46726717)
38. MD Robek BS Boyd FV Chisari 2005 Lambda interferon inhibits hepatitis B and C virus replication J Virol 79 3851 3854 10.1128/JVI.79.6.3851-3854.2005 1:CAS:528:DC%2BD2MXit1ehtr0%3D 15731279 (Pubitemid 40327973)
39. A Meager K Visvalingam P Dilger D Bryan M Wadhwa 2005 Biological activity of interleukins-28 and -29: comparison with type I interferons Cytokine 31 109 118 10.1016/j.cyto.2005.04.003 1:CAS:528:DC%2BD2MXlvVenu70%3D 15899585 (Pubitemid 40910226)
40. SG Maher F Sheikh AJ Scarzello AL Romero-Weaver DP Baker RP Donnelly AM Gamero 2008 IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity Cancer Biol Ther 7 1109 1115 1:CAS:528:DC%2BD1cXhtFWhs7nJ 18698163
41. LA Goldman EC Cutrone SV Kotenko CD Krause JA Langer 1996 Modifications of vectors pEF-BOS, pcDNA1 and pcDNA3 result in improved convenience and expression Biotechniques 21 1013 1015 1:CAS:528:DyaK28XntlGjtb8%3D 8969825
42. JG Segal NC Lee YL Tsung JA Norton K Tsung 2002 The role of IFN-gamma in rejection of established tumors by IL-12 : source of production and target Cancer Res 62 4696 4703 1:CAS:528:DC%2BD38XmsVShsLY%3D 12183428
43. FM Rosenthal K Cronin R Bannerji DW Golde B Gansbacher 1994 Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs Blood 83 1289 1298 1:CAS:528:DyaK2cXitFCqtL4%3D 8118032
44. T Decker M Muller S Stockinger 2005 The yin and yang of type I interferon activity in bacterial infection Nat Rev Immunol 5 675 687 10.1038/nri1684 1:CAS:528:DC%2BD2MXpslakuro%3D 16110316 (Pubitemid 43086170)
45. DB Stetson R Medzhitov 2006 Type I interferons in host defense Immunity 25 373 381 10.1016/j.immuni.2006.08.007 1:CAS:528:DC%2BD28XhtVOjtL%2FI 16979569 (Pubitemid 44354218)
46. K Witte G Gruetz HD Volk AC Looman K Asadullah W Sterry R Sabat K Wolk 2009 Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines Genes Immun 10 702 714 10.1038/gene.2009.72 1:CAS:528:DC%2BD1MXhsV2ks7rP 19798076
47. Meager A (2006) The interferons: characterization and application. Wiley, Weinheim
48. F Belardelli M Ferrantini E Proietti JM Kirkwood 2002 Interferon-alpha in tumor immunity and immunotherapy Cytokine Growth Factor Rev 13 119 134 10.1016/S1359-6101(01)00022-3 1:CAS:528:DC%2BD38XitFWhsrk%3D 11900988 (Pubitemid 34229387)
49. GK bou-Alfa 2006 Hepatocellular carcinoma: molecular biology and therapy Semin Oncol 33 S79 S83 10.1053/j.seminoncol.2006.10.015 (Pubitemid 44908578)
50. SS Thorgeirsson JS Lee JW Grisham 2006 Molecular prognostication of liver cancer: end of the beginning J Hepatol 44 798 805 10.1016/j.jhep.2006.01.008 1:CAS:528:DC%2BD28XisFyqtLc%3D 16488507
51. CL Lai JY Lau PC Wu H Ngan HT Chung SJ Mitchell TJ Corbett AW Chow HJ Lin 1993 Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial Hepatology 17 389 394 10.1002/hep.1840170307 1:STN:280:DyaK3s7os1Sluw%3D%3D 8383088
52. G Fattovich G Giustina S Favarato A Ruol 1996 A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon J Hepatol 24 38 47 10.1016/S0168-8278(96)80184-X 1:STN:280:DyaK28vjtV2nsw%3D%3D 8834023
53. T Okanoue S Sakamoto Y Itoh M Minami K Yasui M Sakamoto K Nishioji T Katagishi Y Nakagawa H Tada Y Sawa M Mizuno, et al. 1996 Side effects of high-dose interferon therapy for chronic hepatitis C J Hepatol 25 283 291 10.1016/S0168-8278(96)80113-9 1:CAS:528:DyaK28Xmtleisrw%3D 8895006 (Pubitemid 26323465)
54. G Dusheiko 1997 Side effects of alpha interferon in chronic hepatitis C Hepatology 26 112S 121S 10.1002/hep.510260720 1:CAS:528:DyaK2sXmt1CktL8%3D 9305675
55. Lawitz EJ, Zaman A, Muir AJ, Shiffman ML, Yoffe B, Zhang T, Souza S, Hausman DF (2009) Interim results from a phase 1b dose-escalation study of 4 weeks of PEG-interferon lambda (PEG-rIL-29) treatment in subjects with hepatitis C virus (HCV) genotype 1 with prior virologic response and relapse to peginterferon alpha and ribavirin. Abstract 170, 48 edn, p 385A
56. Y Tanaka N Nishida M Sugiyama M Kurosaki K Matsuura N Sakamoto M Nakagawa M Korenaga K Hino S Hige Y Ito E Mita, et al. 2009 Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 1105 1109 10.1038/ng.449 1:CAS:528: DC%2BD1MXhtFaju73K 19749757
57. D Ge J Fellay AJ Thompson JS Simon KV Shianna TJ Urban EL Heinzen P Qiu AH Bertelsen AJ Muir M Sulkowski JG McHutchison, et al. 2009 Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 399 401 10.1038/nature08309 1:CAS:528:DC%2BD1MXpvFCrtbw%3D 19684573
58. V Suppiah M Moldovan G Ahlenstiel T Berg M Weltman ML Abate M Bassendine U Spengler GJ Dore E Powell S Riordan D Sheridan, et al. 2009 IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 1100 1104 10.1038/ng.447 1:CAS:528:DC%2BD1MXhtFaju7%2FM 19749758
59. DL Thomas CL Thio MP Martin Y Qi D Ge C O'huigin J Kidd K Kidd SI Khakoo G Alexander JJ Goedert GD Kirk, et al. 2009 Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 798 801 10.1038/nature08463 1:CAS:528:DC%2BD1MXhtFentb%2FJ 19759533
60. G Trinchieri 2003 Interleukin-12 and the regulation of innate resistance and adaptive immunity Nat Rev Immunol 3 133 146 10.1038/nri1001 1:CAS:528:DC%2BD3sXot12gug%3D%3D 12563297 (Pubitemid 37328691)
61. WT Watford M Moriguchi A Morinobu JJ O'Shea 2003 The biology of IL-12: coordinating innate and adaptive immune responses Cytokine Growth Factor Rev 14 361 368 10.1016/S1359-6101(03)00043-1 1:CAS:528:DC%2BD3sXms1Oqsbo%3D 12948519 (Pubitemid 37099449)
62. MP Morrow P Pankhong DJ Laddy KA Schoenly J Yan N Cisper DB Weiner 2009 Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity Blood 113 5868 5877 10.1182/blood-2008-11-190520 1:CAS:528:DC%2BD1MXnsVSksbg%3D 19304955
63. FJ Mennechet G Uze 2006 Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells Blood 107 4417 4423 10.1182/blood-2005-10-4129 1:CAS:528:DC%2BD28Xlt1Cgsbo%3D 16478884 (Pubitemid 43801368)